Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Drug Discovery Today|July 12, 2002
Therapeutic vaccines: realities of today and hopes for the futureMichael Sela, Ruth Arnon, Bilha SchechterMolecular Oncology|April 23, 2009
Cancer therapeutic antibodies come of age: targeting minimal residual diseaseTsipi Ben-Kasus, Bilha Schechter, Michael Sela, et al.Biochemical and Biophysical Research Communications|August 7, 2015
Multimerization of ERBB2/HER2 specific aptamer leads to improved receptor bindingGeorg Mahlknecht, Ruth Maron, Bilha Schechter, et al.NMR in Biomedicine|March 1, 2002
MRI and fluorescence microscopy of the acute vascular response to VEGF165: vasodilation, hyper-permeability and lymphatic uptake, followed by rapid inactivation of the growth factorHagit Dafni, Limor Landsman, Bilha Schechter, et al.Proceedings of the National Academy of Sciences of the United States of America|February 17, 2009
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosisTsipi Ben-Kasus, Bilha Schechter, Sara Lavi, et al.Proceedings of the National Academy of Sciences of the United States of America|May 1, 2013
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growthGeorg Mahlknecht, Ruth Maron, Maicol Mancini, et al.Proceedings of the National Academy of Sciences of the United States of America|September 5, 2013
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2Ruth Maron, Bilha Schechter, Maicol Mancini, et al.Proceedings of the National Academy of Sciences of the United States of America|February 3, 2005
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapyLilach M Friedman, Ariel Rinon, Bilha Schechter, et al.Biochemical and Biophysical Research Communications|April 7, 2019
Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodiesRuth Maron, Bilha Schechter, Nishanth Belugali Nataraj, et al.Pageof 1